Visible results with DUPIXENT
HANDS: 2-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
LEGS: 2-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
LEGS: 2-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
RESULTS
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
ARM: 2-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
ABDOMEN: 3-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
LEGS: 3-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
HANDS: 2-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
LEGS: 2-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
LEGS: 2-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
RESULTS
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
ARM: 2-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
ABDOMEN: 3-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
LEGS: 3-POINT IMPROVEMENT IN IGA PN-S
This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.
to see results
In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).1
Significant nodule clearance at Week 24 in PRIME and PRIME2
RESULTS
Baseline IGA PN-S scores: 3.3 (SD, 0.5) for DUPIXENT, 3.3 (SD, 0.5) for placebo.2
Illustrative representation of nodule clearance based on clinical trial results. Actual individual results may vary.
IGA PN-S ranges from 0 (clear, no nodules) to 1 (almost clear, ≤5 nodules), 2 (mild, 6-19 nodules), 3 (moderate, 20-99 nodules), or 4 (severe, ≥100 nodules).3
- 38% of patients had an IGA PN-S score of 4 (≥100 nodules) at baseline, with 45% of all DUPIXENT patients achieving an IGA PN-S score of 0 or 1 (5 nodules or fewer) at Week 24 vs 16% with placebo (P<0.001, secondary endpoint)1,3,a
a All study participants had ≥20 nodules upon screening and at Day 1 (inclusion criteria).
DUPIXENT showed consistent nodule improvement regardless of patients’ atopic background4
NODULE IMPROVEMENT (IGA PN-S 0 OR 1) AT WEEK 24 REGARDLESS OF
PATIENTS’ HISTORY OF ATOPY4
Definitive conclusions cannot be made for these results as the data were not multiplicity controlled and P values were nominal.
In the PRIME trials, patients were stratified by their history of atopy.
Watch healthcare providers discuss nodule clearance with DUPIXENT
IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; SD, standard deviation.